Viatris Q3 net loss of $128 million; adjusted EPS $0.67, down 11%; guidance raised
Viatris reported third-quarter 2025 total revenues of $3.8 billion, flat on a reported basis, and a U.S. GAAP net loss of $128 million, compared with net earnings of $95 million a year earlier. The company attributed the loss mainly to a reduction in the fair value of its Biocon Biologics preferred shares and higher income tax expense, and it raised and narrowed its 2025 guidance ranges for total revenues, adjusted EBITDA and adjusted EPS.
Key points
- Q3 2025 total revenues were $3.8 billion, flat reported and down 1% on a divestiture-adjusted operational basis; the estimated Indore Impact was about $100 million in the quarter.
- Q3 2025 U.S. GAAP net loss was $(128) million, or $(0.11) per share, versus net earnings of $95 million, or $0.08 per share, in Q3 2024; adjusted EPS was $0.67, down 11% reported.
- 2025 guidance now shows total revenues of $13.9 billion to $14.3 billion (previously $13.5 billion to $14.0 billion) and adjusted EPS of $2.25 to $2.35 (previously $2.16 to $2.30).
- Year-to-date, Viatris returned more than $920 million to shareholders, including $500 million in share repurchases.
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.